GRUNENTHAL GMBH

In News

Grünenthal GmbH Prices €850M Notes Due 2032 - TradingView

TradingView - Sep 17, 2026

Grünenthal announces pricing of €850 million of bonds - TradingView

TradingView - Sep 17, 2026

Top Chronic Pain Drug Companies, 4.01% CAGR to 2034 - Fortune Business Insights

Fortune Business Insights - Sep 10, 2026

Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon - Bloomberg.com

Bloomberg.com - Apr 15, 2026

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development | news aktuell GmbH - Via TT

Via TT - Feb 18, 2026

Grünenthal posts strong financial results for 2025 - The Pharma Letter

The Pharma Letter - Mar 27, 2026

Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist - NTB Kommunikasjon

NTB Kommunikasjon - Jun 29, 2026

Latham & Watkins Advises Grünenthal on €500 Million Bond - Latham & Watkins LLP

Latham & Watkins LLP - Dec 02, 2024

AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America - AstraZeneca

AstraZeneca - Jun 02, 2016

Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management - Fierce Pharma

Fierce Pharma - Apr 12, 2021

Four ways Grünenthal spreads misleading claims about opioids around the world - theexamination.org

theexamination.org - Jul 29, 2025

Federal Circuit Addresses Obviousness of Polymorphs in Grunenthal GmbH v. Alkem Labs. Ltd., No. 2017-1153 (Fed. Cir. Mar. 28, 2019) - JD Supra

JD Supra - Apr 05, 2019

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment